Phaseline

Targets › NECTIN4

NECTIN4 (Nectin-4): drug programs, companies and trials

17 programs from 15 companies in 76 trials: 41 Phase 2, 26 Phase 1, 7 Phase 3, 2 Phase 4; Oncology, Genitourinary; next expected readout Dec 2026.

Seems to be involved in cell adhesion through trans-homophilic and -heterophilic interactions, the latter including specifically interactions with NECTIN1. Does not act as receptor for alpha-herpesvirus entry into cells.; FUNCTION: (Microbial infection) Acts as a receptor for measles virus. (UniProt, Q96NY8)

Open in Phaseline: the race on NECTIN4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
AstellasEnfortumab Vedotin
Nectin-4 binding agent; Tubulin inhibitor
NECTIN4, TubulinPhase 4Metastatic Urothelial Carcinoma; Urothelial Cancer; Locally Advanced or Metastatic Malignant Solid Tumors; Muscle-invasive Bladder Cancer …Dec 2026
Mabwell (Shanghai) Bioscience9MW2821
nectin-4 antibody-drug conjugate with MMAE payload
NECTIN4Phase 3Advanced Urothelial Carcinoma; Urothelial Carcinoma; Cervical Cancer; Triple-Negative Breast CancerDec 2026
Merck & Co. (MSD)EV (Enfortumab Vedotin)
Nectin-4 binding agent; Tubulin inhibitor
NECTIN4, TubulinPhase 3Urinary Bladder Cancer, Muscle-invasive; Bladder Cancer; Metastatic Urothelial CarcinomaMay 2027
Tianjin ConjuStar BiologicsSC-101
anti-NECTIN4 antibody-drug conjugate
NECTIN4Phase 2TNBC - Triple-Negative Breast Cancer; Advanced Solid TumorMar 2027
AkesoAK146D1
Anti-Trop2/Nectin4 bispecific antibody-drug conjugate
TROP2, NECTIN4Phase 2Advanced Non Small Cell Lung Cancer (NSCLC); Advanced Breast Cancer; Advanced Solid TumorsMay 2027
BicycleTxZelenectide pevedotin
anti-NECTIN4 antibody-drug conjugate
NECTIN4Phase 2Metastatic Urothelial Cancer; Breast Cancer; Non-Small Cell Lung CancerMar 2028
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong UniversityBecotatug Vedotin
Anti-NECTIN4 antibody-drug conjugate
NECTIN4Phase 2Head and Neck CancerJun 2028
BeiGeneBGB-A445
anti-NECTIN4 antibody-drug conjugate
NECTIN4Phase 2Non-small Cell Lung Cancer; Urothelial Carcinoma–
Adcentrx TherapeuticsADRX-0706
anti-Nectin-4 antibody-drug conjugate
NECTIN4Phase 1Solid TumorsDec 2026
BicycleTxBT7480
Bicyclic peptide targeting Nectin-4
NECTIN4Phase 1Advanced Solid TumorDec 2026
BicycleTxBT8009
Bicyclic Toxin Conjugate (BTC) targeting Nectin-4-expressing malignancies
NECTIN4Phase 1Urinary Bladder NeoplasmJan 2027
Beijing BiotechEB-DT-NK-UC101
Allogeneic dual-target Nectin-4/HER2 CAR-NK cells with inducible caspase-9 safety switch
NECTIN4, ERBB2Phase 1Bladder CancerJun 2027
Regeneron PharmaceuticalsREGN5678
Anti-NECTIN4 antibody
NECTIN4Phase 1Metastatic Castration-Resistant Prostate Cancer (mCRPC); Metastatic Castration-resistant Prostate CancerNov 2027
Aktis Oncology[225Ac]Ac-AKY-1189
Nectin-4 targeted alpha-emitting radiopharmaceutical
NECTIN4Phase 1Urothelial Carcinoma BladderDec 2027
Innate PharmaIPH4502
Nectin-4-directed antibody-drug conjugate (ADC)
NECTIN4Phase 1Advanced or Metastatic Solid TumorsApr 2028
Context TherapeuticsCT-202
Nectin-4 directed bispecific antibody engaging T cells
NECTIN4Phase 1Triple Negative Breast Cancer (TNBC)Jan 2030
Samsung BioepisE303
nectin-4 targeting antibody-drug conjugate
NECTIN4Phase 1Advanced Solid TumorsJul 2030

Conditions

Urothelial Carcinoma (9) Bladder Cancer (7) Metastatic Urothelial Carcinoma (4) Advanced Urothelial Carcinoma (3) Urothelial Cancer (3) Locally Advanced Bladder Urothelial Carcinoma (3) Advanced Solid Tumors (3) Advanced Solid Tumor (2) Metastatic Castration-resistant Prostate Cancer (2) Cervical Cancer (1) Triple-Negative Breast Cancer (1) Urothelial Carcinoma Bladder (1)

Modalities

small molecule (9), mixed (5), antibody (3)

Companies

BicycleTx (3) Mabwell (Shanghai) Bioscience (1) Aktis Oncology (1) Tianjin ConjuStar Biologics (1) Regeneron Pharmaceuticals (1) Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University (1) Innate Pharma (1) Astellas (1) Samsung Bioepis (1) Beijing Biotech (1) Akeso (1) Context Therapeutics (1) Adcentrx Therapeutics (1) BeiGene (1) Merck & Co. (MSD) (1)

Related targets

Tubulin (2) ERBB2 (1) TROP2 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.